Swainsonine (3), an inhibitor of Golgi a-mannosidase II, is a clinical candidate for cancer treatment. In order to avoid potential problems arising from its co-inhibition of lysosomal mannosidases, we have synthesized 3-benzyloxymethyl analogs of swainsonine (17 and 18). Initial screening of these n
Synthesis and mannosidase inhibitory activity of 6- and 7-substituted analogs of swainsonine
β Scribed by William H Pearson; Erik J Hembre
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- French
- Weight
- 98 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0040-4039
No coin nor oath required. For personal study only.
β¦ Synopsis
Swainsonine (1), an inhibitor of the important glycoprotein-processing enzyme Golgi a-mannosidase II, is a clinical candidate for cancer treatment. Analogs bearing substituents at C-6 and C-7 have been prepared and evaluated as inhibitors of a-mannosidase (jack bean), a closely related enzyme.
π SIMILAR VOLUMES
Three deoxy derivatives 2-4 of the Ξ±-mannosidase inhibitor mannostatin A (1) were synthesized, and their inhibition of Jack bean Ξ±-mannosidase was evaluated in order to elucidate the roles of each of the three hydroxyl groups of the inhibitor. The 1-and 2-deoxy derivatives 2 and 3 retained some
## Abstract Reaction of 1,4βanhydroβ2,3,5βtriβ__O__βbenzylβ1βdeoxyβ1βiminoβDβarabinitol __N__βoxide (**8**) with allyl alcohol produced a 3.6β:β1 mixture of the two pyrrolo[1,2β__b__]isoxazole derivatives **13** and **14**. The major adduct **13** was converted to 7βdeoxycasuarine (**7**), a potent
Two nonhydrolyzable prolyl adenylate analogs, 5Π-O-[N-(L-prolyl)-sulfamoyl]adenosine (L-PSA) and 5Π-O-[N-(D-prolyl)-sulfamoyl]adenosine (D-PSA), were prepared in three steps from 2Π,3Π-di-O-isopropylideneadenosine. Both of these compounds inhibited the in vitro activity of Escherichia coli and human